Office of Cancer Survivorship, The University of Texas MD Anderson Cancer Center, Houston, TX
Katherine Ramsey Gilmore, Patricia Hansberry Chapman, Johnny Rollins, Soo Lee-Kim, Justine Robinson, Ellen Mullen, Haleigh Mistry, Prachee Singh, Robin Coyne, Ana Nelson, William Osai, Karen Stolar, Susan Knippel, Danielle M. Fournier, Tamera Plair, Angela Peek, Maria Alma Rodriguez
Background: Patient reported outcomes (PRO) can be valuable clinical tools to embed the voice of patients into the clinical experience. The use of PROs in the context of cancer survivorship is relatively under-explored. Methods: Disease-specific modules of the MD Anderson Symptom Inventory (MDASI) PRO were integrated into the electronic health record (EHR), and distributed 3-7 days prior to survivorship clinic visits through the patients’ EHR portal. Patients with virtual visits were called 24 hours prior, instructed how to video link, and how to complete the MDASI PRO. For patients who completed the PRO electronically, results were reviewed during clinic visit. High symptom alerts (> = 7) for four key symptoms were established and triggered an automatic message to care teams for review. Results: From Sept 1, 2020 – August 31, 2021, 2,196 PRO surveys were sent to patients with 1,268 submitting results (57.74%) (see Table). Within specific clinics, the submission rates varied greatly between in-person and virtual appointments (33% vs. 83%). Submission rates varied by clinics, with responses ranging from 28.57% - 73.59%. Clinics with higher overall rates had a higher proportion of virtual visits. Conclusions: Electronic distribution of PROs can be successfully integrated into long term survivorship clinic visits. Virtual visits had overall much higher PRO response rates, due to pre-visit workflows which encouraged the completion of PROs. We conclude that patient education and real time support is needed to facilitate patients’ completion of PRO surveys through the electronic portal.
Clinic | # Submitted - Virtual Appt | # Sent - Virtual Appt | % Submitted - Virtual Appt | # Submitted - In Person Appt | # Sent - In Person Appt | % Submitted - In Person Appt | Total % Submitted - All Appt |
---|---|---|---|---|---|---|---|
Breast | 0 | 0 | N/A | 23 | 82 | 28.05% | 28.05% |
GU | 185 | 267 | 69.29% | 11 | 39 | 28.21% | 64.05% |
Head & Neck | 107 | 116 | 92.24% | 128 | 477 | 26.83% | 39.63% |
Lymphoma | 0 | 0 | N/A | 24 | 73 | 32.88% | 32.88% |
Stem cell transplant | 6 | 13 | 46.15% | 52 | 130 | 40.00% | 40.56% |
Thoracic | 1 | 1 | 100.00% | 1 | 6 | 16.67% | 28.57% |
Thyroid | 600 | 681 | 88.11% | 130 | 311 | 41.80% | 73.59% |
Grand Total | 899 | 1078 | 83.40% | 369 | 1118 | 33.01% | 57.74% |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Quality Care Symposium
First Author: Laura LaNiel Tenner
2021 ASCO Annual Meeting
First Author: Stephanie M Smith
2022 ASCO Quality Care Symposium
First Author: Elizabeth Boutin McGrath
2023 ASCO Annual Meeting
First Author: Renee Gilbert